Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Drug Tolerance Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers

NCT03233737
View directory record Official record
Conditions
No Disease State or Condition
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
Combination Product · Device
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 18, 2026, 2:56 AM EDT
Withdrawn Not applicable Interventional

Isoleucine Addition Treatment Effects in a Controlled Diet Study

NCT07329088
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight
Interventions
L-Isoleucine, Low-isoleucine diet
Dietary Supplement · Other
Lead sponsor
Jean L. Fry
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne

NCT03124381
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Cleanser, Acne Mask, Cleanser, Gel-Cream, Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Albuquerque, New Mexico • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional

A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications

NCT00002417
View directory record Official record
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

NCT06442293
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
Treatment 1, Treatment 2, Placebo
Dietary Supplement
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects of Single Oral Dose of 600mg TR-701

NCT00671359
View directory record Official record
Conditions
Healthy
Interventions
TR-701 600mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women

NCT01989949
View directory record Official record
Conditions
Normal Drug Tolerance
Interventions
TP-434 (Eravacycline) reconstituted and administered via an IV infusion
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 18, 2026, 2:56 AM EDT
Completed No phase listed Observational

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

NCT00340132
View directory record Official record
Conditions
Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1983
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

NCT00000654
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Hepatitis B
Interventions
Fialuridine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 18, 2026, 2:56 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

NCT00346398
View directory record Official record
Conditions
Asthma, Allergic Sensitization
Interventions
Oral mucosal immunoprophylaxis (OMIP), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 30 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris

NCT03128723
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Oral Collagen for Rheumatoid Arthritis

NCT00000401
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Oral bovine type II collagen
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Jackson, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
88
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311
View directory record Official record
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions
AZD 1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism

NCT01503164
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep Apnea, Sleep-disordered Breathing
Interventions
Positive Pressure Therapy (PAP), LifeStyle Counseling
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

NCT00815607
View directory record Official record
Conditions
Melanoma
Interventions
INXN-1001, INXN-3001
Drug · Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Newark, Delaware • Savannah, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 18, 2026, 2:56 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction

NCT00982033
View directory record Official record
Conditions
Heart Failure
Interventions
aliskiren, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 18, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Colesevelam HCl On Bile Acid Kinetics

NCT00476710
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Colesevelam HCl
Drug
Lead sponsor
KineMed
Industry
Eligibility
40 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 18, 2026, 2:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

NCT05664243
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
Biological
Lead sponsor
In8bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 18, 2026, 2:56 AM EDT